{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282630","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.654927+00:00","generated_at":"2026-06-21T23:09:10.033540+00:00","sec_items":["2.01","5.07","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Imara completes sale of tovinontrine and PDE9 assets to Cardurion for $34.75M upfront","bullets":["Closed asset sale on Nov 10, 2022; received $34.75M upfront cash payment from Cardurion.","Stockholders approved sale at special meeting on Nov 9: 18,366,825 for, 11,907 against, 47,876 abstain.","Eligible for up to $10M proof-of-concept milestone and $50M regulatory/commercial milestones.","Pro forma financial information to be filed within four business days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282630","json":"https://secwatch.observer/filing/0001193125-22-282630.json","markdown":"https://secwatch.observer/filing/0001193125-22-282630.md","text":"https://secwatch.observer/filing/0001193125-22-282630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/d752591d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:09:10.033540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71ea0204463fd53b4a2c959a580cebb339488def","claim":"Enliven Therapeutics, Inc. completed a disposition involving Cardurion Pharmaceuticals, Inc. for $34,750,000 upfront cash payment (closed 2022-11-10).","evidence_excerpt":"On November 10, 2022, the Asset Sale was consummated and, in accordance with the Asset Purchase Agreement, Cardurion paid to Imara an upfront cash payment of $34,750,000 upon closing of the Asset Sale.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Cardurion Pharmaceuticals, Inc."},{"label":"Consideration","value":"$34,750,000 upfront cash payment"},{"label":"Closing","value":"2022-11-10"}],"fact_type":"ma_transaction"},{"claim_id":"df340da134b718e50775dd4942b3ef76c2cd106c","claim":"Enliven Therapeutics, Inc. shareholders approved Approval of the sale of assets related to the PDE9 program to Cardurion at the 2022-11-09 meeting.","evidence_excerpt":"Proposal No. 1: To approve the sale by the Company to Cardurion of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program, pursuant to the terms of the Asset Purchase Agreement, for an upfront cash payment of $34,750,000 upon closing of the Asset Sale (in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms and conditions of the Asset Purchase Agreement (the “ Asset Sale Proposal ”). This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 18,366,825 11,907 47,876","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}